These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32828214)

  • 1. Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales.
    Perry-Duxbury M; Asaria M; Lomas J; van Baal P
    Value Health; 2020 Aug; 23(8):1027-1033. PubMed ID: 32828214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio.
    van Baal PH; Feenstra TL; Hoogenveen RT; de Wit GA; Brouwer WB
    Health Econ; 2007 Apr; 16(4):421-33. PubMed ID: 17039573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS.
    Perry-Duxbury M; Lomas J; Asaria M; van Baal P
    Pharmacoeconomics; 2022 Feb; 40(2):233-239. PubMed ID: 34697717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation and the postponement of health care costs.
    van Baal PH; Feenstra TL; Polder JJ; Hoogenveen RT; Brouwer WB
    Health Econ; 2011 Apr; 20(4):432-45. PubMed ID: 21210494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research.
    Ochalek J; Lomas J
    Clin Ther; 2020 Jan; 42(1):44-59.e2. PubMed ID: 31955967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?
    Rappange DR; van Baal PH; van Exel NJ; Feenstra TL; Rutten FF; Brouwer WB
    Pharmacoeconomics; 2008; 26(10):815-30. PubMed ID: 18793030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus.
    Meltzer D; Egleston B; Stoffel D; Dasbach E
    Med Care; 2000 Jun; 38(6):679-85. PubMed ID: 10843315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis.
    van Baal P; Meltzer D; Brouwer W
    Health Econ; 2016 Feb; 25(2):237-48. PubMed ID: 25533778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology.
    Olchanski N; Zhong Y; Cohen JT; Saret C; Bala M; Neumann PJ
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):931-40. PubMed ID: 26478989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.
    de Vries LM; van Baal PHM; Brouwer WBF
    Pharmacoeconomics; 2019 Feb; 37(2):119-130. PubMed ID: 30474803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
    Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
    BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care.
    Manns B; Meltzer D; Taub K; Donaldson C
    Health Econ; 2003 Nov; 12(11):949-58. PubMed ID: 14601157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal.
    Morton A; Adler AI; Bell D; Briggs A; Brouwer W; Claxton K; Craig N; Fischer A; McGregor P; van Baal P
    Health Econ; 2016 Aug; 25(8):933-8. PubMed ID: 27374115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating a cost-effectiveness threshold for the Spanish NHS.
    Vallejo-Torres L; García-Lorenzo B; Serrano-Aguilar P
    Health Econ; 2018 Apr; 27(4):746-761. PubMed ID: 29282798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The costs and effectiveness of surveillance of communicable disease: a case study of HIV and AIDS in England and Wales.
    Morris S; Gray A; Noone A; Wiseman M; Jathanna S
    J Public Health Med; 1996 Dec; 18(4):415-22. PubMed ID: 9023800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Intervention Impact on Health Inequality for Resource Allocation.
    Griffin S; Love-Koh J; Pennington B; Owen L
    Med Decis Making; 2019 Apr; 39(3):171-182. PubMed ID: 30819034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach.
    Gandjour A; Müller D
    Appl Health Econ Health Policy; 2014 Oct; 12(5):471-6. PubMed ID: 25027546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.